Neurological Issues During LVAD Support Linked to Increased Mortality
A recent study reveals that neurological complications during LVAD support significantly reduce survival rates among heart failure patients.
8% of patients experienced strokes, while another 8% faced non-stroke neurological events.
Survival rates were 45% for stroke patients and 56% for those with non-stroke complications after two years.
Factors like age and pre-existing conditions were linked to higher mortality post-neurological events.
A comprehensive analysis of 11,739 patients with advanced heart failure has revealed a troubling association between neurological complications and reduced survival rates during support from magnetically levitated left ventricular assist devices (LVADs). Conducted by researchers utilizing the Society of Thoracic Surgeons INTERMACS database, the study highlights the critical need for awareness and management of neurological dysfunction in patients undergoing long-term mechanical circulatory support.
The retrospective cohort study spanned from January 1, 2017, to March 31, 2023, focusing on the incidence and prognostic implications of both stroke and non-stroke neurological adverse events. Among the patients analyzed, 879 (8%) suffered a stroke, while another 972 (8%) experienced non-stroke neurological issues. The remaining 9,888 patients did not report any neurological complications during a median follow-up period of 1.4 years.
Survival outcomes were starkly different for those who experienced neurological events. At the two-year mark, only 45% of stroke patients survived, compared to 56% of those with non-stroke neurological complications. Both groups exhibited significantly lower survival rates than patients without any neurological issues, underscoring the severe impact of these complications on patient outcomes.
The study further revealed that the risk of mortality was 7.3 times higher for patients who had a stroke and 5.1 times higher for those who faced non-stroke neurological events compared to their counterparts without neurological complications. Factors contributing to increased mortality included older age, presence of an implantable cardioverter defibrillator prior to LVAD implantation, and elevated blood urea nitrogen levels, among others.
The findings emphasize the necessity for thorough neurological risk assessments in patients receiving LVAD support. The authors advocate for a unified approach to evaluating both stroke and non-stroke neurological events, suggesting that addressing these complications could lead to improved patient safety and outcomes in advanced heart failure management.
